Human papillomaviruses (HPVs) are a causative factor in over 90% of cervical and 25% of head and neck squamous cell carcinomas (HNSCCs , whereas an enzymatically inactive PTPN13 did not. Twenty percent of HPVnegative HNSCCs had PTPN13 phosphatase mutations that did not inhibit Ras/RAF/MEK/Erk signaling. Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13. These findings show that PTPN13 phosphatase activity has a physiologically significant role in regulating MAP kinase signaling.
Human papillomaviruses (HPVs) are a causative factor in over 90% of cervical and 25% of head and neck squamous cell carcinomas (HNSCCs). The C terminus of the highrisk HPV 16 E6 oncoprotein physically associates with and degrades a non-receptor protein tyrosine phosphatase (PTPN13), and PTPN13 loss synergizes with H-Ras V12 or ErbB2 for invasive growth in vivo. Oral keratinocytes that have lost PTPN13 and express H-Ras V12 or ErbB2 show enhanced Ras/RAF/MEK/Erk signaling. In co-transfection studies, wild-type PTPN13 inhibited Ras/RAF/ MEK/Erk signaling in HEK 293 cells that overexpress ErbB2, EGFR or H-Ras
V12
, whereas an enzymatically inactive PTPN13 did not. Twenty percent of HPVnegative HNSCCs had PTPN13 phosphatase mutations that did not inhibit Ras/RAF/MEK/Erk signaling. Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13. These findings show that PTPN13
Introduction
Malignant transformation often occurs through random, accumulated genetic changes resulting in characteristic features shared by nearly all cancers (Hanahan and Weinberg 2000) . It is estimated that viral gene expression has a role in 20% of cancers. Viral genes frequently target key cellular pathways that are also altered in non-viral cancers. Because viral genes alter these pathways in a mechanistically consistent manner, studies of their function often serve as a starting point to understanding non-viral mechanisms of transformation. In most viral cancers, synergistic cellular changes must occur for malignant progression to occur. Therefore, it is important to study viral gene function in the context of these cellular changes. The following study examines a synergy between human papillomaviruses (HPV) viral oncogene function and cellular changes that lead to invasion. High-risk HPVs promote cancerous growth through overexpression of two multifunctional viral oncoproteins, E6 and E7. Their known transforming functions include inactivation of pRB by E7 and degradation of p53 and activation of telomerase by E6 (Longworth and Laimins 2004) . E6 oncoproteins from HPV subtypes that are high risk for malignant progression also contain a C-terminal PDZ-binding motif (PDZBM), which has a poorly understood yet necessary role in malignant transformation. PDZBMs are short C-terminal amino-acid sequences capable of binding PDZ domain containing proteins (Jelen et al., 2003) . We have previously investigated the transforming effects of the E6 PDZBM of HPV type 16 in HPVrelated head and neck squamous cell cancers (HNSCCs) (Spanos et al., 2008b) and cervical cancer (PN Nowicki et al., unpublished data) and have shown that it physically associates with and induces loss of PTPN13, a non-receptor protein tyrosine phosphatase that contains five PDZ domains. In addition, HPV 16 E6 or short hairpin RNA (shRNA) mediated PTPN13 loss synergizes with H-Ras V12 for invasive growth in vitro and in vivo models of HNSCC (Spanos et al., 2008a (Spanos et al., , 2008b . Besides our data, PTPN13 has been reported as a putative tumor suppressor in a wide range of epithelial cancers (including breast, colon and hepatocellular (Wang et al., 2004; Yeh et al., 2006; Ying et al., 2006) ). Analysis of synergistic changes associated with PTPN13 loss in colon cancers showed that a majority had mutations in the MAP kinase pathway (Wang et al., 2004) .
Although some reports show significant association between Ras mutations and HPV in cervical cancers (Lee et al., 1996; Landro et al., 2008) , direct activating Ras mutations (like H-Ras V12 ) are less common in HNSCCs (Yarbrough et al., 1994; Hardisson 2003; Lu et al., 2006) . Ras pathway stimulation may alternatively be achieved in HNSCCs by overexpression of membrane-bound growth factor receptors, most notably the ErbB family of receptor tyrosine kinases. The four members of this family (ErbB1-4) are commonly overexpressed in HNSCCs and are associated with activation of several major cancer-associated signaling cascades, including signal transducers and activators of transcription (STAT's), Ras/RAF/MEK/Erk (MAP Kinase) and PI3 Kinase/AKT (Ford and Grandis 2003) . ErbB2 specifically is overexpressed in up to 47% of HNSCCs (Cavalot et al., 2007) , and when combined with the expression of E6/E7 causes invasive growth in primary oral keratinocytes, although the mechanism of HPV/ErbB2 synergy and the contribution of the E6 PDZBM were not explored (Al Moustafa et al., 2004) .
Therefore, we have investigated whether the common HNSCC oncogene, ErbB2, synergizes with HPV 16 E6-induced PTPN13 loss to result in invasive growth in vivo. To understand how PTPN13 loss alters cell signaling promoting invasion, we investigated the phosphorylation status of the relevant effector pathway signaling components in the presence or absence of functional PTPN13. We describe a mechanism of PTPN13's phosphatase: the regulation MAP Kinase cascade signaling. Furthermore, we provide evidence that PTPN13 loss of function may have a crucial role in potentiating MAP Kinase cascade signaling downstream of multiple different Ras-activating oncogenes found in both HPV-positive and -negative epithelial cancers.
Results
ErbB2 synergizes with PTPN13 loss allowing invasive growth in vivo Previously, we have shown that H-Ras v12 expression synergizes with HPV 16 E6 or shRNA-mediated PTPN13 loss to allow invasive growth (Spanos et al., 2008b) . Here, we sought to determine if ErbB2, a common HNSCC oncogene that activates Ras, would also cause invasive growth when PTPN13 is absent. In human cancers, ErbB2 overexpression is oncogenic, but in rodent cancer models activating mutations are required for efficient tumor formation (Moasser, 2007) . We therefore cloned mouse ErbB2 cDNA into a retroviral vector and performed site-directed mutagenesis to introduce a transmembrane region point mutation (ErbB2 V660E) corresponding to that present in a constitutively active rat ErbB2 mutant (neuNT) (Moasser, 2007) . Previously described mouse tonsil epithelial (MTE) cell lines stably expressing HPV16 E6, HPV16 E6D 146À151 or shPTPN13 (Hoover et al., 2007; Spanos et al., 2008b) were then transduced with the ErbB2 V660E expression construct. E6D 146À151 is a deletion mutant of HPV16, which degrades p53 but lacks a PDZBM and does not induce the loss of PTPN13 (Spanos et al., 2008b) . The shPTPN13 cells lack PTPN13 due to an shRNA mechanism (Spanos et al., 2008b) . Through western blot, we confirmed that retroviral transduction with ErbB2 V660E increases total and phoshorylated ErbB2 as compared with the parental cells (Figure 1a) . Previously described PTPN13 levels (Spanos et al., 2008b) were not altered by the addition of ErbB2 V660E (not shown).
To determine whether HPV 16 E6 PDZBM-mediated degradation of PTPN13 is required for invasive growth in synergy with ErbB2, we injected 1 Â 10 6 cells from each ErbB2 V660E-expressing cell line subcutaneously into the right hind legs of C57BL/6 mice (5 mice per group). Weekly caliper measurements were used to calculate average mouse leg circumferences and estimate tumor growth rates over time ( Figure 1b ). All mice receiving MTE HPV 16 E6/ErbB2 V660E or MTE shPTPN13/ErbB2 V660E cells formed tumors and met criteria for killing within 50 and 30 days, respectively, but no mice receiving MTE HPV 16 E6D 146À151 /ErbB2 V660E cells showed signs of tumor formation for more than 80 days (Figure 1c ). Representative mouse legs from each group are shown at 2 weeks post-injection ( Figure 1d ). MTE cells expressing both HPV 16 E6 and E7, and ErbB2 V660E formed tumors at the similar rate as HPV 16 E6/ErbB2 V660E (data not shown). Thus, oncogenic forms of ErbB2 ( Figure 1 ) and H-Ras (Spanos et al., 2008b) cells were grown to confluency, serum-starved for 24 h, and protein lysates were collected for immunoblot. Although we observed variation in phospho-AKT levels among the MTE cell lines, we found no correlation between phospho-AKT levels, in vivo invasive growth potential and the presence/absence of PTPN13. However, cell lines with decreased PTPN13 showed increased levels of phospho Erk1/2 (Figure 2a ), a finding that correlates with tumor-forming ability in vivo. MTE cells expressing ErbB2 V660E showed similar results ( Figure 2b ). Immunohistochemistry of mouse tumor samples showed increased levels of phospho-Erk compared with overlying normal epithelium. A representative MTE shPTPN13 ErbB2 V660E tumor is shown in Figure 2c . We also examined phospho-Erk levels in primary human tonsil epithelial cells and those expressing combinations of HPV 16 E6, HPV 16 E6D 146À151 , , as well as in one HPV 16-positive (UPCI-SCC90) and one HPV-negative (UMSCC 84) head and neck squamous cell carcinoma cell line. In previous work, we have shown that UMSCC90 cells have decreased PTPN13 levels compared with UMSCC84 cells (Spanos et al., 2008b) . Consistent with our findings in the mouse, human tonsil epithelial cells expressing E6D 146À151 and E7 showed decreased phospho-Erk levels compared with cells expressing wild-type E6 and E7. The addition of H-Ras V12 further increased phospho-Erk levels. Moreover, UPCI-SCC90 cells show increased phospho-Erk compared with human tonsil epithelial primary cells. Mouse leg circumferences and tumor growth rates were calculated on the basis of weekly caliper measurements of leg dimensions, and mice were killed once tumors reached 20 mm in greatest dimension. The three treatment groups were compared with E6D using two-sided Dunnett adjustment for multiple comparisons developed by Hsu (Hsu 1992) . The shPTPN13 and E6 groups were significantly different than the control group (Po0.0001 and P ¼ 0.009, respectively). The median survival times in the same order of reporting as above were 18, 44 and 80 days, respectively. Interestingly, the HPV-negative UMSCC84 cell line also showed elevated phospho-Erk, although to a lesser degree than UPCI-SCC90. These findings in human and mouse cells suggest that induced loss of PTPN13 in conjunction with Ras activation permits potentiation of signaling through the MAP kinase pathway.
PTPN13 attenuates MEK and Erk phosphorylation
To further study the role PTPN13 has in regulating growth factor receptor-mediated signaling, we performed co-transfection experiments in HEK 293 cells and examined MAP Kinase cascade signaling in response to PTPN13 status, postulating that if loss permits enhanced signaling then replacement of PTPN13 should suppress signaling. Cells were split to equal, subconfluent densities and co-transfected as indicated with mammalian expression vectors for human PTPN13, ErbB2 (wild type), EGFR (ErbB1), H-Ras V12 or an empty vector control. After 24 h of serum starvation, protein lysates were collected and vector expression confirmed by immunoblot. As expected, transfection with ErbB2, H-Ras V12 or EGFR, as compared with empty vector control conditions, increased levels of phospho-Erk, which was inhibited by co-expression of PTPN13 (Figure 3 ). We observed a similar change in phospho-MEK, the immediate upstream activator of Erk. Interestingly, Phospho-AKT levels were not increased by transfection with Ras/ ErbB2/EGFR or inhibited by PTPN13 (Figure 3) . As a previous report showed that PTPN13 may dephosphorylate ErbB2 directly (Zhu et al., 2008) , we also examined levels of phospho-ErbB2 (tyr 1248), and we also observed a small effect in the presence of wild-type PTPN13 (Figure 4 ). These findings show that under serum-starved conditions, PTPN13 consistently attenuates MEK 1/2 and Erk 1/2 phosphorylation in response to activation by various oncogenes common in cervical and/or head and neck cancers.
The phosphatase activity of PTPN13 is required to attenuate MAP Kinase activation Apart from its phosphatase, PTPN13 has many domains likely important for localization, binding potential substrates or possibly regulatory roles (Erdmann, 2003) . The functional significance of the phosphatase domains in preventing transformation has not been shown. In fact, PTPN13 phosphatase domain null mice show only minor phenotypic defects (Wansink et al., 2004; Nakahira et al., 2007) . Contrary to this transgenic mouse data, a recent screen of colorectal cancers suggests loss of phosphatase function that may promote cancer because phosphatase domain mutations frequently co-occurred with mutations in the Ras/MAP Kinase cascade (Wang et al., 2004) . To determine whether PTPN13 phosphatase activity regulates MAP Kinase signaling, we performed site-directed mutagenesis to create a phosphatase dead PTPN13 construct for use in our co-transfection studies. An identical mutation resulting in a phosphatase domain cysteine-to-serine substitution (PTPN13 C2389S) has been shown to abolish PTPN13 catalytic activity (Dromard et al., 2007) . We repeated the HEK 293 transfection assay with expression vectors for EGFR/ErbB2 and either wild-type or C2389S PTPN13 constructs. Immunoblot analysis shows a phosphatase domain function of PTPN13 that is necessary to inhibit MAP Kinase signaling in the presence of ErbB2 or EGFR, as evidenced by increased levels of phospho-Erk and phospho-MEK in PTPN13 C2389S conditions compared with wild-type PTPN13 (Figure 4) . Mutations in HPV-negative HNSCCs do not attenuate MAP kinase signaling The above findings support the hypothesis that loss of PTPN13 phosphatase activity is instrumental in oncogenic signaling. To examine whether HPV-negative human tumors show alternative ways to abrogate PTPN13 enzymatic function, we sequenced PTPN13 exons 44-48 (encoding the PTP domain) from 10 HPVnegative human HNSCC specimens. Two patients showed a total of four mutations in the coding sequence (one patient had three). This percentage (20%) compares well with that observed in colorectal cancers (9%) (Wang et al., 2004) . The mutations were cross-matched with known single-nucleotide polymorphisms to rule out common polymorphisms and were aligned with the protein sequence to determine in which domains the mutations occurred. HNSCC 132 contained one mutation in exon 45, (6874C>T P2276S), and two mutations in exon 46 (7271C>T P2408L and 7316T>C L2423P). HNSCC 134 contained one mutation (c.7205C>T T2386I) in exon 46. The mutations occurring in exon 46 were either within, or close to, important phosphatase domain functional groups (the phosphatase domain-binding loop or WPD loop). Therefore, we chose to determine if these mutations affect PTPN13 phosphatase activity and prevent MAP kinase potentiation in conjunction with wild-type human ErbB2. We performed site-directed mutagenesis to create corresponding mutations in our PTPN13 expression construct and assessed the PTP activity of immunopurified P2408L and L2423P mutant proteins using DifMUP as an artificial substrate from HNSCC 132. Results indicated that, as compared with wild-type PTPN13, both mutants from HNSCC 132 behaved similar to the catalytically dead C2389S PTPN13 version (Supplementary Figure 1 ). We also repeated the transfection assay in HEK 293 cells, and two of the three mutants, one from each HNSCC, did not reduce levels of phosphoErk 1/2 (Figure 5b ). The result of phospho-Erk 1/2 inhibition does not correspond with DifMUP phophatase activity because the P2408L mutant does not show activity but is able to inhibit Erk phosphorylation. An examination of phospho-Erk levels, by immunohistochemistry, in the human cancers from which the mutations were isolated showed focal areas of dense staining compared with little/none in normal tonsillar epithelium (Figure 5c ). Many of HNSCC samples without phosphatase domain mutations also showed increased levels of phospho-Erk (data not shown), indicating that there may be multiple mechanisms through which MAP Kinase activity is increased in HNSCCs. Our findings suggest that PTPN13 phosphatase domain mutations are one mechanism through which increased MAP Kinase activity occurs in HNSCCs. Figure 4 PTPN13s phosphatase activity is required to attenuate MAP Kinase signaling. HEK 293 cells were co-transfected as indicated with (a) ErbB2 or (b) EGFR and either wild-type or phosphatase dead (C2389S) PTPN13 expression constructs. Two days post-transfection serum-starved cells were lysed, subjected to immunoblot analysis using indicated antibodies and densitometry was calculated as described in Supplementary Methods. After transfection with either the wild type or C2398S, the percent phosphorylated MEK, ErbB2 and EGFR is indicated.
MEK inhibition by U0126 abrogates
signaling for the tumorigenic process and assess the possible therapeutic potential of our findings, we examined the levels of phospho-Erk 1/2 in response to the MEK inhibitor U0126 in two tumorigenic cell lines: a cell line derived from a mouse tumor generated by injection with MTE E6E7/ErbB2 V660E cells, and MTE shPTPN13/ErbB2 V660E cells characterized above. For both cell lines, treatment with increasing doses of U0126 correlated with decreasing levels of phospho-Erk (Figure 6a ). To determine the physiological significance of decreased Erk phosphorylation, we examined anchorage-independent growth (AIG) colony-forming efficiencies during U0126 treatment. AIG correlates with invasive potential in vivo (Zhan et al., 2004; Reddig and Juliano, 2005) , and we have previously shown a correlation between PTPN13 loss and AIG in both mouse and human cell lines (Spanos et al., 2008a (Spanos et al., , 2008b . In the cell lines examined, colony-forming efficiencies decreased in a dose-dependent response to U0126 that correlates with a decrease in phospho-Erk (Figure 6b ). These studies provide evidence that HPV 16-related cancers are dependent on enhanced MAP Kinase signaling during invasive growth, and pharmacological inhibition at the level of MEK may serve as a useful therapy.
Discussion
The conversion of a normal epithelial cell to a malignant one requires multiple cellular alterations (Hahn and Weinberg, 2002) . Our findings show that the loss of enzymatic activity of a key phosphatase (PTPN13) synergizes with aberrant MAP Kinase signaling resulting from hyperactivity of epithelial oncogenes, such as ErbB2 and H-Ras, to allow invasive growth in vivo. Importantly, this synergy in potentiating malignant growth is relevant both for HPV-positive as well as HPV-negative tumors. Our data strongly suggest that HPV 16-mediated PTPN13 loss synergizes with ErbB2 activity during invasive growth in HPV-related head and neck cancers, a finding that expands on several previously published reports. ErbB2 and H-Ras have previously been known to synergize with E6 and E7 to allow invasive growth (Al Moustafa et al., 2004; Schreiber et al., 2004) . In addition, ErbB2/EGFR overexpression occurs in a large proportion of cervical cancers (Perez-Regadera et al., 2009) , the majority of which are HPV positive. We show that the HPV 16 E6 PDZBM degrades PTPN13 and this induced loss is needed to synergize with ErbB2. The site(s) where PTPN13 acts to exert this control on MAP kinase signaling is still not clear. Using an independent experimental system, Zhu et al. (2008) have shown that PTPN13 physically associates with and decreases phosphorylation of ErbB2 at phosphotyrosine 1248, and that PTPN13 loss enhances carcinogenic signaling downstream of ErbB2. Our findings are largely in agreement; we show an effect on ErbB2-mediated signaling at the levels of MEK and Erk in response to PTPN13 and also show a change in ErbB2 phosphorylation at tyrosine 1248 that correlated with PTPN13 status. The fact that both ErbB2 and H-RasV12 were potentiated by PTPN13 loss and PTPN13 inhibited MAP kinase signaling downstream of multiple oncogenes (ErbB2, EGFR, H-RasV12) suggests that the phosphatase target that inhibits MAP kinase signaling may not only be limited to ErbB2 tyrosine 1248. Taken together, the above findings suggest a mechanism of how PTPN13 loss of function synergizes with MAP Kinase activating oncogenes to promote invasive growth across both HPV-positive and -negative epithelial cancers. Our identification of non-functional PTPN13 mutants that allow aberrant MAP Kinase signaling in HPV-negative HNSCC specimens is consistent with studies correlating PTPN13 phosphatase domain mutations in colorectal cancers with alterations in the Ras/MAP Kinase cascade (Wang et al., 2004) . Also, mounting evidence points to PTPN13 as a potential tumor suppressor in a broad range of other epithelial cancers, including breast, cervical, gastric and hepatocellular carcinomas (Wang et al., 2004; Yeh et al., 2006; Ying et al., 2006; Revillion et al., 2009) . There still some question as to which domain of PTPN13 is required for MAP kinase inhibition. We show some evidence that did not correlate with phosphatase activity of a mutant and its ability to inhibit Erk phosphorylation. Mutation P2408L showed very little phosphatase activity by DifMUP assay, yet when transfected with ErbB2 is able to inhibit MAP kinase phosphorylation the same as wild type. This finding could be explained by a difference in enzymatic specificity for the native substrate versus the artificial DifMUP assay. An alternative explanation is that other domains of the phosphatase are important in forming a possible complex to inhibit MAP Kinase signaling. The mechanism of inhibition and the binding partners involved will be the focus of future studies.
Although we have shown a specific synergy with H-RasV12 and ErbB2 in vivo, our findings show that PTPN13 loss likewise alters signaling of EGFR, another common epithelial oncogene. Other receptor tyrosine kinases or pathways that activate MAP kinase signaling may also synergize with PTPN13 disruption during invasive growth. A number of MAP Kinase activating oncogenes/mutations have been reported in cancer types known to have decreased or mutated PTPN13. Examples include ErbB3 in the head and neck (Ford and Grandis, 2003) , RAF in colorectal (Wang et al., 2004; Barault et al., 2008) and insulin-like growth factor receptor and RAF in hepatocellular carcinomas (Avila et al., 2006; Hopfner et al., 2008) . Although our findings provide some insight regarding the role of PTPN13 in MAP kinase signaling, many questions remain unanswered, such as what is the target of the phosphatase and what are the roles of the non-phosphatase domains (Erdmann, 2003; Abaan and Toretsky, 2008) . Future work will be required to better understand the complete mechanism of suppression. From a clinical perspective these findings provide rationale for the development of better-targeted therapies in cancers that have lost PTPN13 function. HPVrelated cancers, in particular, offer a distinct opportunity for such therapies, as the viral oncogenes can be rapidly identified in clinical tumor samples and are associated with consistent changes in cell signaling pathways. It would also be possible to test which tumors have synergizing oncogenes that potentiate MAPK signaling. We have shown that Erk phosphorylation and AIG in cells lacking PTPN13 can be inhibited at the level of MEK with U0126; however, U0126 has been shown to be ineffective in vivo, likely due to poor solubility/bioavailability (Wang et al., 2007) . Clinical trials have been undertaken for MEK inhibitors that show greatly improved pharmacological properties in vivo compared with U0126 (Rinehart et al., 2004; Lorusso et al., 2005; Adjei et al., 2008) . These new pharmacological MEK inhibitors may have utility in improving outcomes in HPV-related cancers.
Materials and methods

Retroviral constructs and site-directed mutagenesis
The following mammalian expression vectors were used in transfection experiments: pQCXIX (empty vector) (Clontech, Mountain View, CA, USA), pcDNA3.1 (empty vector), pCMV5-PTPN13 (a gift from Ze'ev Ronai), pcDNA3.1-ErbB2, pBabe Puro-H-Ras v12 , pBabe Puro-EGFR (Addgene plasmid 11011). Methods for creating the activated mouse ErbB2 retroviral construct (pQCXIH-ErbB2 V660E) and the PTPN13 mutant constructs are described in Supplementary Methods.
Retroviral transduction and selection
Mouse tonsil epithelial cell lines stably expressing HPV 16 E6/ E7, E6, E6D 146À151 , or shPTPN13 have been described previously and were routinely cultured in E-Media (Hoover et al., 2007; Spanos et al., 2008b) . Retroviral transduction with pQCXIH-ErbB2 V660E was performed using standard methods (Hoover et al., 2007) . Cell lines were selected in E-Media containing 25-100 mg/ml Hygromycin until non-transduced controls had died (approximately 10 days). Following selection, cells were maintained in E-Media with 5 mg/ml Hygromycin.
In vivo invasive growth Experiments were carried out as has been previously described (Hoover et al., 2007; Spanos et al., 2008b) . Examination of these tumors by a pathologist showed invasive growth into muscle and capillary/lymphatic growth as was seen in our past model (Spanos et al., 2008a, b) . In brief, MTE cells were harvested from tissue culture plates using trypsin (0.25%), and resuspended at 10 3 cells/ml in E-Media. Using an 18-gauge needle, 100 ml of cell suspension was injected subcutaneously in the right hind leg of each C57BL/6 mouse. Leg circumference was estimated by weekly caliper measurements and using the equation:
), where a is longest leg dimension, and b the shortest. Mice were humanely killed once tumors reached 2 cm in greatest dimension, or the animal became emaciated or had functional leg impairment. An 80-day survival study of 20 mice in four equally sized groups was analysed using the log-rank test with Kaplan-Meier estimated survival functions (Figure 1c) . The one mortality in the E6D group was related to a non-tumor-related anesthesia death. This is indicated in the survival graph.
Cell lysis and immunoblot
Cell lysis and immunoblot analyses were carried out as described previously (Hoover et al., 2007) . Blots were developed on Kodak Biomax MR film using SuperSignal West Pico and Femto Chemiluminescent Substrates (Pierce Biotechnology, Rockford, IL, USA). The following antibodies were used: Anti Fap-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-15356), Anti GAPDH (Ambion, Austin, TX, USA, AM4300), Antiphospho-AKT1/PKBa (ser 473) (Upstate, Billerica, CA, USA, 05-669), Anti-phospho-p44/42 MAPKinase (thr202/204) (Cell Signaling, Danvers, MA, USA, #9101), Anti-phospho-erbB2 (tyr 1248) (Upstate, 06-229), Anti-MapKinase Erk1/Erk2 (Calbiochem, San Diego, CA, USA, 442704), Anti-AKT/PKB (Upstate, 05-591), Anti-phospho-MEK1/2 (ser217/221) (Cell Signaling, # 9154), and anti-human-c-erbB2 oncoprotein (DakoCytomation, Carpinteria, CA, USA, A 0485).
Transfection assay HEK 293 cells were routinely cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Twenty-four hours before transfection, cells were split and plated at 6 Â 10 6 cells/10 cm plate. Co-transfections were carried out as per manufacturers instructions using Polyfect (Qiagen, Valencia, CA, USA, 301105) and 4 mg of each indicated plasmid. Twenty-four hours posttransfection, plates were washed twice with phosphate-buffered saline and serum-starved for 16-24 h in Dulbecco's modified Eagle's medium before protein lysis.
Anchorage-independent growth assay and MEK inhibitor (U0126) studies U0126 (Cell Signaling # 9903) was solubilized in dimethlysulfoxide at 8 mg/ml before being added to Dulbecco's modified Eagle's medium at indicated concentrations. To create the MTE E6E7 ErbB2 V660EA tumor cell line, tumor tissue was dissected from the leg of a freshly killed male C57BL/6 mouse, injected 3 weeks before with MTE E6E7 ErbB2 V660E cells. Tissue was finely minced using a scalpel and subsequent treatment with Dispase II. Cells were cultured using previously described methods (Hoover et al., 2007) . Indicated amounts of U0126 was applied to the cells in Eagle's minimum essential medium for 48 h before lyses and subsequent immunoblots.
Anchorage-independent growth assays were carried out by applying a 100 ml base layer of 1% noble agar to 12 mm transwells with 0.4 mM polyester membrane inserts (Corning, Lowell, MA, USA, # 3460) and allowed to solidify at 4 1C. Cells were suspended at 2 Â 10 3 cells/ml in a mixture of 0.33% noble agar and E-Media at 37 1C. A volume of 500 ml of this suspension was added in triplicate to transwells and allowed to harden 5 min at 4 1C. Transwells were added to sterile, 12-well tissue culture plates containing enough growth media to cover the 1% agar layer (approximately 1.5 ml). Media was changed every other day and supplemented with U0126 at indicated concentrations. Cells were grown in suspension for 17 days. Colonies reaching diameters of 100 mm or greater were counted. AIG percent colonyforming efficiency was determined using the equation: (AIG colonies/cells seeded) Â 100. Analysis of variance statistical analysis was used to calculate significance.
Patient samples
Formalin-fixed, paraffin-embedded oropharyngeal squamous cell carcinoma cases and tonsil tissues from tonsillectomies
